scPharmaceuticals (SCPH) Stock Price, News & Analysis

Company Overview

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Key Stats

• Today's Range: $3.22 to $3.43
• 50-Day Range: $3.14 to $3.68
• 52-Week Range: $3.08 to $6.54
• Volume: 403,526 shs
• Average Volume: 247,628 shs
• Market Capitalization: $162.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

scPharmaceuticals Stock Analysis - MarketRank™

scPharmaceuticals scored higher than 85% of companies evaluated by MarketBeat, and ranked 157th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

scPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

scPharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for scPharmaceuticals are expected to grow in the coming year, from ($1.53) to ($1.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of scPharmaceuticals is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of scPharmaceuticals is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

scPharmaceuticals has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.21% of the outstanding shares of scPharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

scPharmaceuticals has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.

Change versus previous month

Short interest in scPharmaceuticals has recently decreased by 10.53%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

scPharmaceuticals does not currently pay a dividend.

Dividend Growth

scPharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.09

Percentage of Shares Shorted

11.21% of the outstanding shares of scPharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

scPharmaceuticals has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.

Change versus previous month

Short interest in scPharmaceuticals has recently decreased by 10.53%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

scPharmaceuticals has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for scPharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for SCPH on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

3 people have added scPharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, scPharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.52% of the stock of scPharmaceuticals is held by insiders.

Percentage Held by Institutions

89.52% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SCPH Stock Analysis - Frequently Asked Questions

How have SCPH shares performed this year?

scPharmaceuticals' stock was trading at $3.54 at the beginning of 2025. Since then, SCPH stock has decreased by 8.2% and is now trading at $3.25.
View the best growth stocks for 2025 here.

How were scPharmaceuticals' earnings last quarter?

scPharmaceuticals Inc. (NASDAQ:SCPH) announced its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. The business had revenue of $6.10 million for the quarter, compared to analyst estimates of $6.50 million. scPharmaceuticals had a negative net margin of 264.60% and a negative trailing twelve-month return on equity of 244.93%.

When did scPharmaceuticals IPO?

scPharmaceuticals (SCPH) raised $96 million in an initial public offering (IPO) on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Who are scPharmaceuticals' major shareholders?

scPharmaceuticals' top institutional shareholders include AIGH Capital Management LLC (8.34%), King Luther Capital Management Corp (5.71%), Suvretta Capital Management LLC (3.68%) and J. Goldman & Co LP (2.44%). Insiders that own company stock include Orbimed Advisors Llc and 5Am Partners Iv, Llc.
View institutional ownership trends.

How do I buy shares of scPharmaceuticals?

Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of scPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that scPharmaceuticals investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 5/14/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCPH
• CUSIP: N/A
• CIK: 1604950
• Web: www.scpharma.com
• Phone: (617) 517-0730
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.00
• High Stock Price Target: $18.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +361.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-54,810,000.00
• Net Margins: -264.60%
• Pretax Margin: -264.60%
• Return on Equity: -244.93%
• Return on Assets: -68.56%

Debt

• Debt-to-Equity Ratio: 1.66
• Current Ratio: 8.08
• Quick Ratio: 6.89

Sales & Book Value

• Annual Sales: $13.59 million
• Price / Sales: 11.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.04 per share
• Price / Book: 3.13

Miscellaneous

• Outstanding Shares: 50,040,000
• Free Float: 47,278,000
• Market Cap: $162.63 million
• Optionable: Optionable
• Beta: 0.11